TREMFYA DIN 02566877
Health Canada record
| Active ingredient(s) | GUSELKUMAB 100 MG |
|---|---|
| Dosage form | Solution |
| Route | Subcutaneous |
| Schedule | PRESCRIPTION; SCHEDULE D |
| Class | Human |
| ATC | L04AC16 GUSELKUMAB |
| Original market date | 04-May-2026 |
| Current status date | 04-May-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing GUSELKUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02469758 | TREMFYA | JANSSEN INC | Solution | GUSELKUMAB 100 MG | Marketed |
| 02559137 | TREMFYA | JANSSEN INC | Solution | GUSELKUMAB 200 MG | Approved |
| 02559145 | TREMFYA | JANSSEN INC | Solution | GUSELKUMAB 200 MG | Marketed |
| 02570890 | TREMFYA | JANSSEN INC | Solution | GUSELKUMAB 45 MG | Approved |
| 02559153 | TREMFYA I.V. | JANSSEN INC | Solution | GUSELKUMAB 200 MG | Marketed |
| 02487314 | TREMFYA ONE-PRESS | JANSSEN INC | Solution | GUSELKUMAB 100 MG | Marketed |